Back to resultsAn Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
Primary Purpose
Dry Eye With Sjögren's Syndrome
Status
Terminated
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
KCT-0809 ophthalmic solution
Sponsored by
About this trial
This is an interventional trial for Dry Eye With Sjögren's Syndrome focused on measuring Dry eye syndromes, Corneal diseases, Conjunctival diseases
Eligibility Criteria
Inclusion Criteria:
- Dry eye patients with Sjögren's syndrome finished KCT1301 study
Exclusion Criteria:
- Patients with poor adherence to medication of study drug in KCT1301 study
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
KCT-0809
Arm Description
Outcomes
Primary Outcome Measures
Incidences of adverse events
Secondary Outcome Measures
Score of the corneal staining
Full Information
NCT ID
NCT02503176
First Posted
July 17, 2015
Last Updated
March 2, 2018
Sponsor
Kissei Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT02503176
Brief Title
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Terminated
Why Stopped
Discontinuation of the development
Study Start Date
undefined (undefined)
Primary Completion Date
May 29, 2017 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kissei Pharmaceutical Co., Ltd.
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye With Sjögren's Syndrome
Keywords
Dry eye syndromes, Corneal diseases, Conjunctival diseases
7. Study Design
Study Phase
Phase 3
8. Arms, Groups, and Interventions
Arm Title
KCT-0809
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
KCT-0809 ophthalmic solution
Primary Outcome Measure Information:
Title
Incidences of adverse events
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Score of the corneal staining
Time Frame
52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Eligibility Criteria
Inclusion Criteria:
Dry eye patients with Sjögren's syndrome finished KCT1301 study
Exclusion Criteria:
Patients with poor adherence to medication of study drug in KCT1301 study
Facility Information:
City
Multiple Locations
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
We'll reach out to this number within 24 hrs